Liver Cirrhosis Archives

Tackling NASH cirrhosis

Annual Reports, Biopharma/Biotech Annual Report, Business, Clinical Trials, Issue Archives, June 2021, Liver Cirrhosis, Med Ad News, Melanoma, Non-alcoholic steatohepatitis (NASH), PD-1/PD-L1 inhibitors, R&D

Galectin Therapeutics is one of the only biotech companies with an active Phase IIb/III clinical trial for NASH cirrhosis. Galectin recently launched a site dedicated to its study, NAVIGATE: https://navigatenash.com/. Also, the Journal for ImmunoTherapy of Cancer recently published Phase I clinical research showing belapectin, Galectin Therapeutics’ galectin-3 inhibitor, enhances tumor response in combination with anti-PD-1 therapy. Med Ad News discussed these and other topics with Dr. Pol Boudes, CMO of Galectin.

June 10, 2021/by Andrew Humphreys

Merck and Hanmi Ink $870 Million NASH Deal

Business, Clinical Data, Deals, Glucagon-Like Peptide-1 (GLP-1) Analogs, Licensing, Liver Cirrhosis, Non-alcoholic steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)

Merck entered into an exclusive licensing deal with Hanmi Pharmaceutical for the development, manufacture and commercialization of efinopegdutide for nonalcoholic steatohepatitis (NASH).

August 4, 2020/by BioSpace

Mallinckrodt’s Terlipressin Recommended for Approval by U.S. FDA Advisory Committee

Advisory Committees, FDA, Hepatorenal Syndrome Type 1 (HRS-1), Kidney Failure, Liver Cirrhosis, PDUFA, Vasopressin 1a (V1a) receptor antagonists

The Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food and Drug Administration voted to recommend approval for Mallinckrodt’s investigational agent terlipressin to treat adults with hepatorenal syndrome type 1 (HRS-1).

July 15, 2020/by PR Newswire

Akero’s EFX Shows Promise in NASH Trial

Analysis, Analysts, Biopsies, Clinical Trials, Complete Response Letter, FDA, Liver Cirrhosis, New Drug Applications, R&D

South San Francisco-based Akero Therapeutics presented results from a 16-week analysis of secondary and exploratory endpoints in the company’s Phase IIa BALANCED clinical trial of efruxifermin in nonalcoholic steatohepatitis (NASH).

July 1, 2020/by BioSpace

AbbVie’s Mavyret Approved for Hep C in Pediatric and Adolescent Patients

Adolescents, Approvals, Children, FDA, FDA/Regulatory, Hepatitis C, Liver Cirrhosis, Liver Inflammation, National Health Service (NHS), New Indications, U.S. Centers for Disease Control and Prevention

The U.S. FDA approved AbbVie’s Mavyret for all six strains of hepatitis C in children ages 12 to 17 years. The drug was approved for adults 18 years or older during 2017.

May 1, 2019/by BioSpace

Gilead teams up with insitro for experimental NASH treatments

Alphabet, Business, Cell damage, Diabetes, Excess fat, Fatty liver disease (NASH), Google, Inflammation, Liver Cancer, Liver Cirrhosis, Machine Learning, Obesity, Partnerships, Verily

Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.

April 16, 2019/by Reuters Health